Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) is an emerging tick-borne virus causing viral hemorrhagic fever with a case fatality rate up to 27%. It is endemic in East Asia and has spread to the United States, posing a growing public health concern. Currently, there is no targeted antiviral therapy or licensed vaccine for SFTSV. Vaccine development is crucial, especially for the elderly, who are most at risk. Recent research has explored various vaccine approaches, including live-attenuated, DNA, whole inactivated virus, viral vector, protein subunit, and mRNA vaccines. These vaccines aim to induce strong immune responses and protect against SFTSV infection. Animal models, such as IFNAR KO mice and aged ferrets, have been used to study vaccine efficacy. Live-attenuated vaccines based on SFTSV NSs have shown promise in protecting aged ferrets. DNA vaccines encoding Gn and Gc have also demonstrated protective effects. Viral vector vaccines, such as rVSV and rVACV, have shown cross-protection against SFTSV and related viruses. Protein subunit vaccines, including GnH-ferritin nanoparticles, have shown potential in inducing strong immune responses. mRNA vaccines have also shown efficacy in protecting against SFTSV. Despite progress, challenges remain in ensuring vaccine safety, efficacy, and accessibility. Future research should focus on optimizing vaccine platforms, enhancing immunogenicity, and addressing logistical issues for widespread use.Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) is an emerging tick-borne virus causing viral hemorrhagic fever with a case fatality rate up to 27%. It is endemic in East Asia and has spread to the United States, posing a growing public health concern. Currently, there is no targeted antiviral therapy or licensed vaccine for SFTSV. Vaccine development is crucial, especially for the elderly, who are most at risk. Recent research has explored various vaccine approaches, including live-attenuated, DNA, whole inactivated virus, viral vector, protein subunit, and mRNA vaccines. These vaccines aim to induce strong immune responses and protect against SFTSV infection. Animal models, such as IFNAR KO mice and aged ferrets, have been used to study vaccine efficacy. Live-attenuated vaccines based on SFTSV NSs have shown promise in protecting aged ferrets. DNA vaccines encoding Gn and Gc have also demonstrated protective effects. Viral vector vaccines, such as rVSV and rVACV, have shown cross-protection against SFTSV and related viruses. Protein subunit vaccines, including GnH-ferritin nanoparticles, have shown potential in inducing strong immune responses. mRNA vaccines have also shown efficacy in protecting against SFTSV. Despite progress, challenges remain in ensuring vaccine safety, efficacy, and accessibility. Future research should focus on optimizing vaccine platforms, enhancing immunogenicity, and addressing logistical issues for widespread use.